Apogee Therapeutics Inc.
Apogee Therapeutics Initiates Dosing in Phase 1 Trial for APG333
Summary
Apogee Therapeutics, Inc. announced on December 10, 2024, the initiation of dosing of healthy volunteers in its Phase 1 clinical trial for APG333, a novel subcutaneous half-life extended monoclonal antibody targeting thymic stromal lymphopoietin (TSLP). The trial is being conducted to evaluate the safety, tolerability, and pharmacokinetics of APG333 as a potential treatment for asthma, chronic obstructive pulmonary disease (COPD), and broader inflammatory and immunology (I&I) conditions. The study is designed as a double-blind, placebo-controlled, first-in-human, single-ascending dose trial and is expected to enroll approximately 32 healthy adults into four cohorts. Interim data from the trial is anticipated in the second half of 2025.
Profitelligence Alerts
Get alerts for APGE
Be first to know when Apogee Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Apogee Therapeutics Inc.
Apogee Therapeutics Inc. is a biotechnology company focused on the development of biologic therapies for atopic dermatitis and other inflammatory diseases. The primary purpose of Apogee Therapeutics is to leverage its expertise in immunology and protein engineering to address unmet needs in the treatment of autoimmune and inflammatory conditions. The company is active in sectors such as healthcare and pharmaceuticals, contributing to advancements in medical biotechnology. Apogee Therapeutics plays a significant role in the financial market by advancing cutting-edge therapies in the biopharmaceutical landscape. It engages in research and development efforts to bring innovative biologic medicines to patients, thereby impacting the broader pharmaceutical industry. The company's focus on treating inflammatory diseases aligns with an increasing demand for novel treatments arising from a greater understanding of disease mechanisms and patient needs. By developing specialized biologic solutions, Apogee Therapeutics positions itself as a key player in addressing some of the challenges associated with chronic inflammatory conditions, ultimately pushing forward the boundaries of therapeutic options available to patients worldwide.
Official SEC Documents
Advertisement